+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Liver Diseases Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

  • PDF Icon


  • 125 Pages
  • April 2021
  • Region: Global
  • Mordor Intelligence
  • ID: 4896059
The liver diseases therapeutics market is expected to register a CAGR of nearly 11.01% during the forecast period with a revenue of approximately USD 19,745 million in 2020 and expected to reach USD 36,812 million by 2026. The market will show rapid growth due to the increasing incidence of liver diseases, an increase in consumption of alcohol and improper diet, and rising government initiatives of providing vaccines and growing awareness.

The rising number of cases of COVID-19 have found liver disease involvement. The cause of liver injury in COVID‐19 can be attributed to multiple factors including virus‐induced systemic inflammation, hypoxia, hepatic congestion, and drug-induced liver disease. Among patients with cirrhosis, COVID‐19 has been associated with hepatic decompensation and liver‐related mortality. Additionally, COVID‐19’s impact on healthcare resources has adversely affected the delivery of care and outcomes of patients with chronic liver disease. Therefore, there has been a decrease in the treatment, diagnosis, and follow-up of patients with liver disease, which had negative consequences in the overall healthcare industry. Also, the clinical trials of drugs have been slow down as most of the companies have delayed the start for most of the new studies in several countries.

Chronic liver diseases (CLDs) are major public health problems, globally. The liver is, in many ways, the reflection of a person’s health and should play a central role in public health policies across the world. The mortality rate due to chronic liver disease continues to rise driven largely by a spike in nonalcoholic fatty liver disease (NAFLD), according to results from an analysis of national data.

According to a study “Burden of Liver Diseases in the World”, which was published in 2019, liver disease accounts for approximately 2 million deaths per year worldwide, out of which, 1 million are due to complications of cirrhosis and 1 million are due to viral hepatitis and hepatocellular carcinoma. Thus, cirrhosis is the 11th most common cause of deaths across the world, and liver cancer is 16th leading cause of death, combined, they account for 3.5% of all deaths across the world. Also, chronic liver disease mortality is expected to rise in the United States, driven largely by a spike in nonalcoholic fatty liver disease (NAFLD). The rising incidence of liver diseases helped in driving the market’s growth. Therefore increasing liver diseases has helped in driving the overall market.

In the United Kingdom, the primary causes of liver diseases include alcohol, obesity, and viral hepatitis. Furthermore, about 1,000 liver transplants are performed each year, and due to insufficient liver donors, people are dependent on the therapeutics available in the market. All the aforementioned factors are thus expected to drive the market’s growth.

Furthermore, with the increasing prevalence of liver diseases, government and other not-for-profit organizations are playing a crucial role in the rising awareness about liver diseases across the globe. Hence all these organizations are found promoting the awareness of the liver-related diseases and support for research and development for the prevention, treatment and cure of liver diseases.

Key Market Trends

Anti Viral Drugs Segment is Expected to Dominate the Market During the Forecast Period

With the rising prevalence of liver diseases and the increasing consumption of alcohol, the demand for liver diseases therapeutics is increased significantly.

Due to the COVID-19 pandemic, it has been found that currently, there is no antiviral drug that is directed against SARS-CoV-2 and many patients with COVID-19 are administered antivirals authorized for other therapeutic indications. A recent study published in 2021, has shown that although arbidol treatment does not seem to be significantly associated with liver injury complications, the overall use of antiviral drugs increases the risk of liver injury for critically ill patients with COVID-19. Antiviral drugs are widely used to treat COVID-19 but are not found to be recommended for critically ill patients. However, the effect of antiviral treatment on liver injury in critically ill patients is not yet clear.

The antiviral drugs are a class of medication used for HBV (hepatitis B virus) that are found to be effective in suppressing the HBV viral load while reducing the risk of developing cirrhosis and hepatocellular carcinoma. Some of the FDA-approved drugs include Mavyret, Zepatier, and Vosevi. These drugs have been widely used for many years and are safe and effective, especially for patients with signs and symptoms of moderate-to-severe liver impairment or other serious liver problems.

Therefore, the antiviral drug segment holds a major market share, and it is expected to maintain its lead position during the forecast period. This is attributed to the high incidence of virus-infected liver diseases, including Hepatitis. Thus, antiviral drugs are often taken to maintain the suppression of the hepatitis B virus and long-term complications associated with hepatitis B, including liver disease and impairment. Thus, there is a need for liver transplantation and hepatocellular carcinoma.

Also, there are various drug approvals, along with the commercialization of several anticipated pipeline drugs, which are expected to drive the growth of the market studied.

North America is Expected to Dominate the Liver Disease Therapeutics Market

The market is found to be dominated by North America owing to the presence of research and academic institutes conducting clinical trial studies in the region. Changing lifestyle such as increasing consumption of alcohol, unhealthy diets have also increased the incidences of liver disease. Moreover, growing patient awareness levels and the introduction of new products targeting unmet medical needs are expected to drive regional market growth over the forecast period.

Since the COVID-19 outbreak, the market has been negatively impacted due to the supply chain and market disruption, and by its financial impact on firms and financial markets. The pandemic has negatively impacted the pharmaceutical industry in terms of the supply and demand for different drugs. Similarly, it is also expected to impact the overall growth of the global liver disease therapeutics market.

There has been an increase in the number of deaths due to liver diseases, along with the rising incidence of liver cancer. According to the Centers for Disease Control and Prevention, in the United States, between 800,000 and 1.4 million people are suffering from chronic hepatitis B infection. Currently, in the United States, there about 43,000 hepatitis B cases each year. Furthermore, about 15%-25% of the people suffering from chronic hepatitis B are expected to develop serious liver diseases, such as cancer, cirrhosis (scarring of the liver), or liver failure, all of which can be fatal.

According to the Canadian Liver Foundation, Non-alcoholic fatty liver disease (NAFLD is the most common liver disease in Canada affecting about 20% of Canadians. The most common cause of fatty liver disease in Canada is obesity. In 2018, almost 30% of Canadians 18 and older (roughly 7.3 million adults) reported height and weight that classified them as either overweight or obese. This helps in increasing liver diseases and thereby boosting the overall market demand.

Based an article published by Mayo Clinic 2019, has found that there are therapies that have been available to treat some forms of liver disease, including hepatitis C and autoimmune hepatitis. Drug therapy thus may effectively treat a potentially life-threatening condition associated with cirrhosis and other chronic liver diseases, according to a new study by Mayo Clinic researchers.

Therefore, due to the rising prevalence of liver diseases, the management of liver diseases evolved rapidly, and several therapeutic options are available in the market, primarily related to the prevention of, both, progression of liver disease and anticipated liver morbidity and mortality. Moreover, growing patient awareness levels and the introduction of new products targeting the unmet medical needs are expected to drive regional market growth over the forecast period.

Competitive Landscape

There are various companies that are found investing in their R&D to develop innovative and advanced treatment drugs for liver diseases. Therefore research and development of high efficient and less or no side effects pharmaceutical drugs would drive the market in the near future. The companies are also found focusing on organic growth strategies such as product launches, product approvals and others such as patents and events.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in the Incidence of Liver Diseases
4.2.2 Increase in the Consumption of Alcohol and Improper Diet
4.2.3 Rising Government Initiatives of Providing Vaccines and Growing Awareness
4.3 Market Restraints
4.3.1 Side-effects and Risks Associated with Drugs
4.3.2 Stringent FDA approvals and Other Government Regulations
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Treatment Type
5.1.1 Anti Viral Drugs
5.1.2 Targeted Therapy
5.1.3 Immunosuppressant Drugs
5.1.4 Chemotherapy Drugs
5.1.5 Immunoglobulin
5.1.6 Vaccines
5.1.7 Other Treatment Types
5.2 By End User
5.2.1 Hospitals
5.2.2 Ambulatory Surgery Centers
5.2.3 Other End User
5.3 Geography
5.3.1 North America United States (By Treatment Type and By End User) Canada (By Treatment Type and By End User) Mexico (By Treatment Type and By End User)
5.3.2 Europe Germany (By Treatment Type and By End User) United Kingdom (By Treatment Type and By End User) France (By Treatment Type and By End User) Italy (By Treatment Type and By End User) Spain (By Treatment Type and By End User) Rest of Europe (By Treatment Type and By End User)
5.3.3 Asia-Pacific China (By Treatment Type and By End User) Japan (By Treatment Type and By End User) India (By Treatment Type and By End User) Australia (By Treatment Type and By End User) South Korea (By Treatment Type and By End User) Rest of Asia-Pacific (By Treatment Type and By End User)
5.3.4 Middle East and Africa GCC (By Treatment Type and By End User) South Africa (By Treatment Type and By End User) Rest of Middle East and Africa (By Treatment Type and By End User)
5.3.5 South America Brazil (By Treatment Type and By End User) Argentina (By Treatment Type and By End User) Rest of South America (By Treatment Type and By End User)
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Astellas Pharma Inc.
6.1.3 Bristol-Myers Squibb Company
6.1.4 Gilead Sciences
6.1.5 GlaxoSmithKline Plc
6.1.6 F. Hoffmann-La Roche Ltd
6.1.7 Merck & Co. Inc.
6.1.8 Novartis AG
6.1.9 Sanofi AG
6.1.10 AbbVie Inc.
6.1.11 Endo International Plc
6.1.12 Pfizer Inc.
6.1.13 Takeda Pharmaceutical
6.1.14 Alnylam Pharmaceuticals, Inc.
6.1.15 Provectus Biopharmaceuticals Inc

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences
  • GlaxoSmithKline Plc
  • F. Hoffmann-La Roche Ltd
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi AG
  • AbbVie Inc.
  • Endo International Plc
  • Pfizer Inc.
  • Takeda Pharmaceutical
  • Alnylam Pharmaceuticals, Inc.
  • Provectus Biopharmaceuticals Inc